Last Update 17 Jun 26

LCTX: Bullish Coverage And Ophthalmology Milestones Will Drive Future Stock Upside

Analysts have adjusted their price target for Lineage Cell Therapeutics to $5.50, with the update supported by recent bullish coverage initiations and a higher target from Street research. Key valuation inputs such as discount rate, revenue growth, profit margin and future P/E assumptions remain broadly consistent with prior estimates.

Analyst Commentary

Street research on Lineage Cell Therapeutics has focused on how the updated US$5.50 price target lines up with the company’s execution risks and potential growth opportunities. Recent coverage has framed expectations around whether Lineage can deliver against the assumptions already embedded in valuation models, rather than introducing entirely new drivers.

Bullish Takeaways

Bullish analysts highlight that the higher price target is supported by coverage initiations that view current assumptions for revenue growth and profitability as achievable within existing modeling frameworks.
The updated target is seen as consistent with prior discount rate and P/E assumptions. Some bullish analysts interpret this as a sign that the stock’s upside case does not rely on aggressive changes to core valuation inputs.
Positive commentary points to the idea that additional research coverage can improve visibility for Lineage Cell Therapeutics, which may help close any gap between current pricing and the new target level if execution aligns with expectations.
Supportive analysts frame the US$5.50 target as a reflection of confidence that Lineage can meet key milestones already factored into forecasts, rather than requiring materially better operating performance.

Bearish Takeaways

Bearish analysts caution that, even with a higher target, valuation remains sensitive to any change in discount rate, revenue growth, or margin assumptions, given the reliance on future cash flows and earnings.
There is concern that execution risk around delivering the modeled growth path could weigh on the stock if clinical, regulatory or commercial timelines do not align with expectations embedded in the current P/E framework.
Some cautious views emphasize that recent target adjustments rely on inputs that are broadly unchanged, so any adverse development affecting those assumptions could lead to renewed downward revisions.
A more guarded stance highlights the possibility that additional bullish coverage may raise expectations faster than Lineage Cell Therapeutics can deliver concrete financial results, which could add volatility if sentiment shifts.

What’s in the News for Lineage Cell Therapeutics

Lineage Cell Therapeutics reported 36-month data from its Phase 1/2a study of RG6501 (OpRegen) for geographic atrophy secondary to age-related macular degeneration, with gains in best corrected visual acuity and optical coherence tomography imaging that indicated partial restoration of outer retinal structure and reappearance of an RPE layer in treated eyes. (Source: Foundation Fighting Blindness Retinal Therapeutics Innovation Summit 2026)
The company highlighted that anatomical and functional measures in Cohort 4 patients, including changes in BCVA and retinal layer areas on OCT, persisted through 36 months after a single subretinal administration of OpRegen, with effects more prominent in patients who had extensive OpRegen cell therapy coverage of atrophic areas. (Source: Clinical study NCT02286089)
Lineage Cell Therapeutics disclosed in its January 2026 shareholder letter that its AlloSCOPE platform, which is designed to produce millions of doses of cell-based products from a single cell line, is being evaluated for large scale production needs in islet cell therapy for Type 1 Diabetes, alongside other programs such as new corneal endothelial (COR1) and additional undisclosed cell programs. (Source: January 2026 shareholder letter)
The company reported achievement of a first milestone under its worldwide collaboration with Roche and Genentech for OpRegen, which is being developed as an allogeneic retinal pigment epithelium cell therapy for geographic atrophy secondary to age-related macular degeneration. (Source: January 2026 shareholder letter)
Lineage Cell Therapeutics announced the launch of COR1, a preclinical corneal endothelial cell therapy program targeting corneal endothelial disease, including Fuchs Endothelial Corneal Dystrophy and Bullous Keratopathy, using its AlloSCOPE platform to manufacture off the shelf corneal endothelial cells intended to address global donor shortages. (Source: Company product-related announcement)

Valuation Changes for Lineage Cell Therapeutics

Fair Value: $5.50 remains unchanged, indicating no shift in the modeled intrinsic value per share.
Discount Rate: 7.15% to 7.13%, a marginal reduction that slightly lowers the required return applied to Lineage Cell Therapeutics.
Revenue Growth: 72.38% to 72.38%, effectively unchanged, suggesting the same long term top line trajectory is still being used.
Net Profit Margin: 24.22% to 24.22%, essentially flat, with no material adjustment to expected long term profitability.
Future P/E: 112.57x to 112.50x, a very small decrease that leaves the long run earnings multiple assumption broadly intact.

1 view

Key Takeaways

Strong clinical progress, industry partnerships, and rising demand for regenerative therapies position Lineage for accelerated adoption and substantial long-term revenue growth.
Scalable manufacturing and nondilutive funding provide financial flexibility and operational leverage, supporting margin expansion and minimizing shareholder dilution.
High dependence on a narrow pipeline and regulatory uncertainty, combined with competition and ongoing losses, threaten sustainable growth and financing prospects.

Catalysts

About Lineage Cell Therapeutics

A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The ongoing global increase in age-related and degenerative diseases, particularly dry AMD, combined with emerging long-term benefits from OpRegen's clinical trials (3-year sustained vision gains), positions Lineage to tap into a rapidly expanding patient population, likely driving substantial future top-line revenue growth as population aging continues.
Broader acceptance of regenerative medicine as a standard clinical approach, with independent validation from multiple peer programs and increased payer/researcher interest, indicates an enabling environment for Lineage's products to see accelerated adoption rates and more favorable reimbursement-catalysts expected to boost commercialization prospects and net margin expansion.
Maturation of Lineage's pluripotent stem cell-derived pipeline (OpRegen, OPC1, and additional cell types like for hearing loss) and near-term milestones (e.g., Phase II/III trial progression, regulatory designations, expansion into new indications) increase the likelihood of pipeline de-risking events that could lead to licensing deals, approvals, and eventual significant revenue inflection points.
Strategic partnerships (notably with Roche/Genentech) and ongoing pursuit of nondilutive funding (e.g., milestone payments, grants like CIRM, and new collaborations) provide Lineage with enhanced financial flexibility to extend cash runway, minimize shareholder dilution, and improve future cash flow and net margins if partnership milestones are achieved.
Advances in scale and cost-efficiency of allogeneic (off-the-shelf) cell manufacturing, with proven in-house GMP production of millions of doses, support scalable expansion and operational leverage, setting the stage for improved gross margins and stronger long-term earnings growth as additional programs advance toward the clinic.

Lineage Cell Therapeutics Earnings and Revenue Growth

Lineage Cell Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Lineage Cell Therapeutics's revenue will grow by 72.4% annually over the next 3 years.
Analysts assume that profit margins will increase from -434.4% today to 24.2% in 3 years time.
Analysts expect earnings to reach $18.3 million (and earnings per share of $0.06) by about June 2029, up from -$64.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $181.2 million in earnings, and the most bearish expecting $-52.4 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 112.6x on those 2029 earnings, up from -4.7x today. This future PE is greater than the current PE for the US Biotechs industry at 16.4x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.13%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Lineage remains highly dependent on the timely and successful clinical development and commercialization of a very narrow pipeline, especially OpRegen, and if clinical or regulatory setbacks occur, this could severely impact future revenues and shareholder value due to lack of diversification.
The company continues to operate at a substantial loss, highlighted by a net loss of $30.5 million for the quarter and a cash runway only into Q1 2027, raising ongoing risks of future shareholder dilution or inability to finance operations, which threatens future earnings and margins.
Increasing competition from other regenerative medicine companies with similar RPE cell transplant products (e.g., Astellas) could compress Lineage's commercial opportunity, challenge its market leadership, and put downward pressure on prospective revenue and margins.
The sector's prolonged underperformance and investor skepticism toward early-stage biotech, compounded by rising capital costs and interest rates, could persistently limit access to non-dilutive funding and force more expensive or dilutive capital raising, impacting future net margins and overall financial sustainability.
Regulatory uncertainty and limited precedent for later-stage cell therapy approvals, combined with turnover at the FDA and evolving endpoints for target indications, could extend timelines, delay revenue recognition, and increase the costs and risks associated with product commercialization.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $5.5 for Lineage Cell Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $3.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $75.7 million, earnings will come to $18.3 million, and it would be trading on a PE ratio of 112.6x, assuming you use a discount rate of 7.1%.
Given the current share price of $1.2, the analyst price target of $5.5 is 78.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Lineage Cell Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Aging Trends And Regenerative Medicine Will Open New Avenues